Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962616 | 1.00 | CYP3A4 (0.35) | CYP3A4MAPK1LGALS3ALDH1A1MEN1 | |
| SCHEMBL7999756 | 1.00 | CYP3A4 (0.35) | CYP3A4MAPK1LGALS3ALDH1A1MEN1 | |
| SCHEMBL14968526 | 1.00 | CYP3A4 (0.35) | CYP3A4MAPK1LGALS3ALDH1A1MEN1 | |
| SCHEMBL7458744 | 1.00 | CYP3A4 (0.35) | CYP3A4MAPK1LGALS3ALDH1A1MEN1 | |
| SCHEMBL12691080 | 0.90 | CYP3A4 (0.34) | CYP3A4MAPK1LGALS3ALDH1A1MEN1 | |
| SCHEMBL4279232 | 0.86 | GSTP1 (0.32) | LGALS3 | |
| SCHEMBL13657211 | 0.86 | GSTP1 (0.32) | LGALS3 | |
| SCHEMBL8015303 | 0.82 | CA12 (0.42) | LGALS3ALDH1A1 | |
| SCHEMBL12691651 | 0.81 | CYP3A4 (0.33) | CYP3A4MAPK1ALDH1A1 | |
| SCHEMBL5691368 | 0.78 | FUCA1 (0.44) | MAPK1LGALS3ALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417144-B1 | SYNTHESIS OF 2'-O-FUCOSYLLACTOSE | GLYCOM AS (DK) | 2017-08-23 | — | — | EP | disclosed |
| EP-2417143-B1 | SYNTHESIS OF 2'-O-FUCOSYLLACTOSE | GLYCOM AS (DK) | 2016-12-21 | — | — | EP | disclosed |
| US-9012625-B2 | Method for the synthesis of a trisaccharide | GLYCOM A/S (DK) | 2015-04-21 | — | — | US | disclosed |
| US-8927698-B2 | Method for the synthesis of a trisaccharide | GLYCOM A/S (DK) | 2015-01-06 | — | — | US | disclosed |
| US-20130131334-A1 | METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE | Glycom A/S Danmarks Tekniske Universitet (DK) | 2013-05-23 | — | — | US | disclosed |
| US-20120116065-A1 | NOVEL METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE | GLYCOM A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| EP-2417144-A1 | SYNTHESIS OF 2 ' -O-FUCOSYLLACTOSE | Glycom A/S (DK) | 2012-02-15 | — | — | EP | disclosed |
| EP-2417143-A1 | SYNTHESIS OF 2'-O-FUCOSYLLACTOSE | Glycom A/S (DK) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115935-A1 | SYNTHESIS OF 2 ' -O-FUCOSYLLACTOSE | GLYCOM A/S (DK) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115934-A1 | SYNTHESIS OF 2'-O-FUCOSYLLACTOSE | GLYCOM A/S (DK) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116065-A1 | NOVEL METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE | FUT6, FUT5, GALE | CYP3A4 1433/4885MAPK1 2780/4885LGALS3 335/4885 |
| US-20130131334-A1 | METHOD FOR THE SYNTHESIS OF A TRISACCHARIDE | UGGT1, FUT6, MAN1B1 | CYP3A4 908/4885MAPK1 1780/4885LGALS3 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.